Schering gets EU OK to buy Organon

Schering-Plough has to give a little to get a lot. The company has agreed to sell off more than 20 of its animal vaccines and medicines to win regulatory approval to buy Organon Biosciences. The $14.4 billion deal will give Schering a stable of women's health meds and central nervous system drugs, and will bolster its late-stage pipeline, too.

Among the products to be sold are vaccines for E. coli in swine, flu and tetanus in horses, and rabies in several species. They also include veterinary antibiotics, insulin, and more.

- read the report from at

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.